Business Context and Reporting Period
This Form 8-K is a current report filed by Ginkgo Bioworks Holdings, Inc. on August 29, 2025. The filing addresses Item 8.01 (Other Events) regarding the resolution of stockholder derivative litigation.
Key Financial Metrics
The filing does not report standard operating financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to the settlement of legal proceedings:
- Settlement Payment to Company: $4,125,000 (funded by insurance).
- Plaintiffs' Counsel Fee Request: $2,750,000 (to be paid from the settlement amount).
Material Changes
The material event reported is the entry into a Stipulation and Agreement of Settlement on May 27, 2025, resolving three stockholder derivative actions: Hu v. Baker et al., Bowers v. Kelly et al., and In re Ginkgo Bioworks Holdings, Inc. Stockholder Derivative Litigation. On August 21, 2025, the United States District Court for the Northern District of California granted preliminary approval of this settlement.
Outlook, Risks, and Contingencies
Contingencies: The settlement is subject to final approval by the Court. A final hearing is scheduled for December 18, 2025, at 1:30 p.m. PST.
Terms of Settlement:
- The Company will receive $4,125,000 funded by insurance.
- The Company will adopt and maintain specific corporate governance and other reforms.
- Plaintiffs will dismiss the derivative actions with prejudice and provide releases regarding the alleged matters.
Risks: The filing notes that the summary is qualified by the full text of the Stipulation of Settlement and Notice of Pendency, which are available on the company's investor relations website.
Investor Verification Checklist
- Verify the outcome of the final hearing scheduled for December 18, 2025, to confirm the settlement receives final court approval.
- Review the full text of the Stipulation of Settlement to understand the specific corporate governance reforms the Company must adopt.
- Confirm the net financial impact to the Company after the deduction of the $2,750,000 legal fee award from the $4,125,000 insurance payment.